C13H12FeN2O, monoclinic, P21/n (no. 14), a = 5.9035(2) Å, b = 20.7111(6) Å, c = 9.1403(3) Å, β = 90.0762(16)°, V = 1117.57(6) Å3, Z = 4, Rgt(F) = 0.0282, wRref(F2) = 0.0656, T = 150(2) K
The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the ortho-rhom-bic space group Pbca wi...
Biferrocenyi, C₅H₅,Fe,C₅H₄. C₅H₄ .Fe.C₅H₅., crystallises in the monoclinic system with a = 10.35, b ...
The title compound, [Fe(C7H9N2)2], crystallizes with two crystallographically independent molecules ...
C42H66FeN4O6, orthorhombic, P212121 (no. 19), a = 10.7723(9) Å, b = 11.7128(8) Å, c = 33.392(3) Å, V...
C21H21FeNO, monoclinic, P121/a1 (no. 14), a = 7.329(7) Å, b = 17.343(3) Å, c = 13.618(5) Å, ? = 95.0...
C23H19FeN3O3S, monoclinic, P21/n (no. 14), a = 13.1372(6) Å, b = 9.6866(5) Å, c = 15.9700(8) Å, β = ...
C17H14FeN4, monoclinic, P21/c, a = 11.8213(11) Å, b = 10.3610(10) Å, c = 11.8552(11) Å, α = γ = 90°,...
WOS: 000234198700025C21H21FeNO, monoclinic, P12(1)/alpha 1 (no. 14), a = 7.329(7) angstrom, b = 17.3...
C19H17FeN3O4S, triclinic, P1̄ (no. 2), a = 7.1964(3) Å, b = 10.9732(4) Å, c = 11.6391(4) Å, α = 80.8...
C16H13FeN3O2S, triclinic, P1̅, a = 8.1311(9) Å, b = 11.6852(13) Å, c = 17.044(2) Å, α = 102.754(6)°,...
C13H12N2O3S, monoclinic, P21/c (no. 14), a = 12.3541(8) Å, b = 14.3818(10) Å, c = 7.3757(5) Å, β = 9...
R factor = 0.054; wR factor = 0.135; data-to-parameter ratio = 13.9. In the title compound, C15H12FN...
C21H14ClF3FeN2O, triclinic, P1̅ (no. 2), a = 7.8754(6) Å, b = 10.9326(10) Å, c = 11.8418(9) Å, α = 7...
The title compound, C20H15FN2O2, adopts an almost planar conformation. The oxadiazole ring makes dih...
R factor = 0.038; wR factor = 0.083; data-to-parameter ratio = 13.2. The crystal structure of the ti...
The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the ortho-rhom-bic space group Pbca wi...
Biferrocenyi, C₅H₅,Fe,C₅H₄. C₅H₄ .Fe.C₅H₅., crystallises in the monoclinic system with a = 10.35, b ...
The title compound, [Fe(C7H9N2)2], crystallizes with two crystallographically independent molecules ...
C42H66FeN4O6, orthorhombic, P212121 (no. 19), a = 10.7723(9) Å, b = 11.7128(8) Å, c = 33.392(3) Å, V...
C21H21FeNO, monoclinic, P121/a1 (no. 14), a = 7.329(7) Å, b = 17.343(3) Å, c = 13.618(5) Å, ? = 95.0...
C23H19FeN3O3S, monoclinic, P21/n (no. 14), a = 13.1372(6) Å, b = 9.6866(5) Å, c = 15.9700(8) Å, β = ...
C17H14FeN4, monoclinic, P21/c, a = 11.8213(11) Å, b = 10.3610(10) Å, c = 11.8552(11) Å, α = γ = 90°,...
WOS: 000234198700025C21H21FeNO, monoclinic, P12(1)/alpha 1 (no. 14), a = 7.329(7) angstrom, b = 17.3...
C19H17FeN3O4S, triclinic, P1̄ (no. 2), a = 7.1964(3) Å, b = 10.9732(4) Å, c = 11.6391(4) Å, α = 80.8...
C16H13FeN3O2S, triclinic, P1̅, a = 8.1311(9) Å, b = 11.6852(13) Å, c = 17.044(2) Å, α = 102.754(6)°,...
C13H12N2O3S, monoclinic, P21/c (no. 14), a = 12.3541(8) Å, b = 14.3818(10) Å, c = 7.3757(5) Å, β = 9...
R factor = 0.054; wR factor = 0.135; data-to-parameter ratio = 13.9. In the title compound, C15H12FN...
C21H14ClF3FeN2O, triclinic, P1̅ (no. 2), a = 7.8754(6) Å, b = 10.9326(10) Å, c = 11.8418(9) Å, α = 7...
The title compound, C20H15FN2O2, adopts an almost planar conformation. The oxadiazole ring makes dih...
R factor = 0.038; wR factor = 0.083; data-to-parameter ratio = 13.2. The crystal structure of the ti...
The title iron(II) complex, [Fe(C16H12NO2)2], crystallizes in the ortho-rhom-bic space group Pbca wi...
Biferrocenyi, C₅H₅,Fe,C₅H₄. C₅H₄ .Fe.C₅H₅., crystallises in the monoclinic system with a = 10.35, b ...
The title compound, [Fe(C7H9N2)2], crystallizes with two crystallographically independent molecules ...
DOI
Add to ORKG